Partnerships
Turning potential into progress
At JCR, we are firm believers that two heads are better than one. It's why we actively seek opportunities to combine our unique technology and expertise with visionary thinking, using our partnership models to drive innovation forward and bring next-generation products to patients.
Our mindset
Proactive
We harness breakthrough therapeutic platforms like J-Brain Cargo® to unlock new possibilities and expand accessibility across markets with high unmet treatment needs.
Focused
We take a special interest in delivering precision therapies to target conditions that have traditionally been difficult to treat.
Innovative
We continuously find ways to push scientific boundaries and remain at the forefront of solving complex healthcare challenges.
Partnership Models
Platform based
Since its founding in 1975, JCR has built proprietary technologies rooted in its biotechnology expertise and research capabilities. J-Brain Cargo® is one such platform. It enables drugs to cross the blood-brain barrier and reach the brain. This core technology can be applied across a broad range of modalities, from small molecules to enzymes and antibodies, as well as oligonucleotides, lipid nanoparticles, and gene therapies.
JCR has also developed JUST-AAV, a proprietary gene therapy platform based on adeno-associated virus. This engineered AAV enables efficient gene delivery to target tissues and organs while reducing distribution to sites where accumulation is undesirable.
By providing these proprietary technologies to partners seeking efficient delivery to target tissues, JCR aims to support the creation of innovative medicines.
Asset based
JCR is advancing a diverse development pipeline, much of which focuses on rare diseases including mucopolysaccharidosis. Programs span multiple stages, from preclinical research through ongoing clinical trials.
In areas with significant unmet medical need, these assets represent new therapeutic possibilities. Through strategic licensing and collaborative clinical development, JCR seeks to accelerate global expansion of its pipeline and deliver new treatment options to patients worldwide.
Partner Companies
Technology Licensing
(As of April 1, 2026)
| 2016 | J-Brain Cargo® | PeptiDream Inc. | Macrocyclic peptides |
|---|---|---|---|
| 2023 | J-Brain Cargo® | Alexion, AstraZeneca Rare Disease | Neurodegenerative Diseases |
| 2023 | J-Brain Cargo® | Angelini Pharma | Epilepsy |
| 2023 | J-Brain Cargo® | Alexion, AstraZeneca Rare Disease | Oligonucleotides |
| 2025 | JUST-AAV | Modalis Therapeutics Corporation | Gene Therapy |
| 2025 | JUST-AAV | Alexion, AstraZeneca Rare Disease | Gene Therapy |
| 2025 | J-Brain Cargo® | Acumen Pharmaceuticals, Inc. | Alzheimer’s Disease |
Product Licensing
(As of April 1, 2026)
| 2022 | JR-471 | MEDIPAL HOLDINGS CORPORATION | Fucosidosis | Out-Licensing |
|---|---|---|---|---|
| 2023 | JR-446 | MEDIPAL HOLDINGS CORPORATION | Mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B) |
Out-Licensing |
| 2025 | JR-479 | MEDIPAL HOLDINGS CORPORATION | GM2 gangliosidosis | Out-Licensing |
| 2025 | Givinostat | Italfarmaco S.p.A. | Duchenne muscular dystrophy | In-Licensing |
Distribution Partner
(As of April 1, 2026)
| Epoetin Alfa BS Injection JCR | KISSEI PHARMACEUTICAL CO., LTD. | Sales Outsourcing (Japan) |
|---|---|---|
| Darbepoetin Alfa BS Injection JCR | KISSEI PHARMACEUTICAL CO., LTD. | Sales Outsourcing (Japan) |
| Agalsidase Beta BS I.V. Infusion [JCR] | Sumitomo Pharma Co., Ltd. | Sales Outsourcing (Japan) |
| IZCARGO™ | Sumitomo Pharma Co., Ltd. | Co-promotion (Japan) |
| Agalsidase Beta BS I.V. Infusion [JCR] | Menagen Pharmaceutical Industries LLC | Development and sales outsourcing (9 countries in the Middle East, North Africa, and Turkey) |
For business partnership inquiries, please contact us using the link below.
Clicking the link will open your email application.